In particular, genetic mutations, inflammatory cytokines, PD-L1 and CTLA-4 levels, and tumor-infiltrating lymphocytes (TIL) should be assessed, as their expression has been related to a favorable response to treatment. This evidence concerns the gene CTLA4 and neoplasm.